Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping anti-HER2 antibodies after prolonged complete response in metastatic HER2-positive breast cancer
MOH_2025-12-27_015564Phase 2Recruiting
- Sponsor
- ד"ר דניאלה כץ
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pertuzumab in HER2-positive breast cancer, sponsored by ד"ר דניאלה כץ. Primary endpoint: Progression-free survival after anti-HER2 discontinuation. Started Nov 2025; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on MOH_2025-12-27_015564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-27_015564.